Was the U.S. government cheated on DNA decoder?
The scribblings of Henry Huang helped start the great race to map the human genome, and they may help settle allegations that the U.S. government got robbed on the way to the finish.

Cultivating Prosperous Partnerships
Like dedicated gardeners — who know that it’s not enough to merely plant seeds and bulbs to create a flourishing landscape — pharmaceutical companies have come to realize that tending to their partnering relationships is critical to achieving the best results.

Harvesting the Fruits of Plant Genomics
Pioneer Hi-Bred President Richard McConnell explains how geneticists are revolutionizing crops, yields — even the humble corn chip

Pa. uses tobacco settlement to fund biotech
Its efforts reflect a larger trend of states targeting bioscience as a source of future jobs and revenue. Overall, at least 41 states have instituted initiatives in recent years to attract new life-sciences companies, according to research conducted by Columbus, Ohio-based nonprofit organization Battelle Memorial Institute

Biotech stocks show indication of rebounding
Biotechnology stocks, down sharply since late last year because of a raft of bad news, appeared to begin a comeback last week as clinical trials results were leaked in advance of a major scientific meeting.

Chinese cloning control required
Strict ethical guidelines are needed in China to calm public fears about new cell technologies such as cloning, one of the country’s leading scientists has said.

Veteran biotech investors offer tips from trenches
These market-hardened biotech investors made three basic recommendations: be patient, take profit when you can, and don’t believe hype. Although this may sound like Investing 101, their lessons have the added credibility of being based on real life.

Genome Group Rips Human Cloning
Scientists at the Human Genome Organization have condemned plans for human cloning, saying it raises deep concerns over moral issues and arguing that the technology was far from mature and its side effects were unknown.

As Pipelines Wither, Pharma and FDA Explore Whether Microarrays are Ready for Primetime
When can the pharmaceutical industry start trusting the technology? When should it make the leap from investigative, experimental technique to industry standard? And should the FDA start using microarray data to make critical decisions about the safety and efficacy of new drugs?

Research ‘leak’ hits Genentech
Genentech’s shares dropped 12.5 per cent after details of the biotechnology company’s research abstracts for next month’s American Society of Clinical Oncology appeared to have been leaked.